Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB Pharmaceuticals highlights first quarter progress

UCB Pharmaceuticals highlights first quarter progress

29th April 2010

UCB Pharmaceuticals has hailed the success of its business activities during the first quarter of 2010, during which the company successfully introduced a number of key products.

In the company’s latest interim report, UCB highlighted the “solid growth” of the drugs Cimzia, Vimpat and Neupro, all of which have been rolled out in a number of key European markets in the last three months.

It estimates that in excess of 116,000 patients are now being treated using the three treatments, identifying Neupro as being the most widely used, with more than 54,700 people now benefiting from the drug in Europe.

The company expects to record total annual revenue of around three billion euros (2.6 billion pounds) in 2010, with the growth of the new drugs set to account for a significant portion of this.

Roch Doliveux, chief executive officer of UCB, said: “Our new products Cimzia, Vimpat and Neupro are building momentum and laying the foundation for UCB’s future growth.”

This comes after UCB published data from two clinical trials earlier this month, which demonstrate the effectiveness of Neupro as a treatment for Parkinson’s disease and restless legs syndrome.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.